"systemic targeted radionuclide therapy for metastatic melanoma"
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201700036C
- Awardee
-
Viewpoint Molecular Targeting, Inc. UEI RDZCK3F6AU73
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,944,651
Award facts
- Opportunity
-
- N44CO7701794 Solicitation number
- Contract value 100% obligated
- $1,944,651.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Iowa City, IA 52246, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,944,651 |
About this award
Viewpoint Molecular Targeting, Inc. was awarded a $1,944,651 firm fixed price definitive contract from the Department of Health and Human Services' National Institutes of Health National Cancer Institute to provide services for "Systemic Targeted Radionuclide Therapy for Metastatic Melanoma." The contract is set aside for total small businesses. Under the contract, Viewpoint Molecular Targeting will conduct research and development activities related to receptor-targeted alpha particle therapy using lead-212 for the treatment of metastatic melanoma. Work will include preclinical pharmacology, toxicology, biodistribution and dosimetry studies; cGMP peptide manufacturing; scaled radionuclide production and validation; and clinical trial preparation. All work will be conducted in Iowa City, Iowa and is expected to be completed by September 17, 2019.
Quick answers
Who was awarded contract HHSN261201700036C?
HHSN261201700036C was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2017.
How much is contract HHSN261201700036C worth?
The government has obligated $1,944,651 on HHSN261201700036C.
Was contract HHSN261201700036C competed?
The extent of competition for HHSN261201700036C was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award